Trial Profile
12-Month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 100ug NeuroVax Once Monthly Intramuscular Injection Versus Interferon ß-1a Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2013
Price :
$35
*
At a glance
- Drugs IR 902 (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Immune Response BioPharma
- 05 Dec 2013 New trial record
- 24 Nov 2013 This trial is expected to begin enrolling patients in quarter 2, 2015, according to an Immune Response BioPharma media release. The company is discussing funding of NeuroVax development with US government funding agencies.